Biotech Stocks Could Use A Win — Will The First Quarter Offer That?Investors Business Daily • 04/08/21
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del MutationBusiness Wire • 03/26/21
Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del MutationBusiness Wire • 03/24/21
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 DiabetesBusiness Wire • 03/10/21
5 Stocks to Watch Amid Continued Expansion in the Biotech IndustryZacks Investment Research • 03/09/21
Forget GameStop, AMC, and Sundial: These Are the Best Stocks to Buy Right NowThe Motley Fool • 03/07/21
Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/03/21
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at Cowen 41st Annual Health Care Conference (Transcript)Seeking Alpha • 03/02/21